Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

DexCom, Inc.

DXCM

FAVORABLE

May 27, 2026

Research Conclusion

DexCom is a leading CGM medical device company at a trough multiple post-FY2024 execution stumble. At ~$62 vs. PWFV $73-85, upside +18-37%. CMS T2 non-insulin coverage decision (end-2026/early-2027) is a binary asymmetric catalyst. New CEO Jake Leach's $1M open-market purchase + Q1 2026 beat = credibility rebuild. Position 2-4% growth allocation; aggressive add below $45.

Company Overview & Moat Assessment

DexCom, Inc. (NASDAQ: DXCM) is a leading continuous glucose monitoring (CGM) medical device company. Products: G7 (15-day sensor), G8 (in development), Stelo (OTC consumer). FY2025 revenue $4.3B (+9%); $1.1B FCF; non-GAAP EPS $1.95. Net cash positive. CEO Jake Leach (post-Sayer; insider). Market: ~12M covered T1 + insulin-requiring T2 patients; CMS T2 non-insulin coverage would expand TAM by additional 12M covered lives.

▲ Bull Case

  • ◆CMS favorable + G8 + gross margin 65%: FY28 EPS $4+; multiple 28x → $112 (+81%)
  • ◆Stelo scales to $300M+ FY27: Consumer CGM validated → +15-25%
  • ◆Ireland manufacturing ramps: Gross margin to 65%+ → +10-15%

▼ Bear Case

  • ◆CMS denies T2 non-insulin coverage: Revenue growth slows; multiple to 18-20x → -19-27%
  • ◆Abbott Gen 4 multi-analyte disrupts: Competitive pressure → -19%
  • ◆Stelo doesn't scale: Consumer thesis broken → -11%
Primary Debate on Wall Street

“Bulls: Best-in-class CGM at trough multiple; CMS catalyst asymmetric. Bears: Structural gross margin impairment; Abbott competition. Decision-margin: CMS decision + gross margin trajectory.”

Top Catalysts
  • ◆CMS T2 non-insulin coverage decision — End 2026/early 2027 — Up if favorable — EXTREME
  • ◆Q2-Q3 2026 EPS beats — Aug-Nov 2026 — Up — HIGH
  • ◆G7 15-day US conversion — End 2026 — Up — MEDIUM-HIGH
  • ◆G8 FDA submission — 2027 — Up — HIGH
  • ◆$1B+ buyback execution — Ongoing — Up — MEDIUM
  • ◆Ireland manufacturing ramp — 2027 — Up — MEDIUM-HIGH
  • ◆Stelo revenue milestones — Quarterly — Up — MEDIUM
  • ◆Abbott Gen 4 launch — 2027-2028 — Down — MEDIUM
  • ◆Non-invasive CGM clearance — 2029+ — Down — EXTREME (long-term)
Top Risks
  • ◆CMS denies coverage — Probability: 40% — Severity: HIGH
  • ◆Abbott competition — Probability: 35% — Severity: MEDIUM-HIGH
  • ◆Stelo underperforms — Probability: 30% — Severity: MEDIUM
  • ◆Gross margin stuck — Probability: 30% — Severity: MEDIUM-HIGH
  • ◆G8 delay — Probability: 25% — Severity: MEDIUM
  • ◆Non-invasive CGM disruption — Probability: 15% — Severity: EXTREME (long-term)
  • ◆Multiple compression — Probability: 25% — Severity: MEDIUM

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/DXCM/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.